Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Period to Evaluate the Safety, Tolerability, and Efficacy of SAT-3247 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT07872306 is registered in ClinicalTrials.gov with Satellos Bioscience, Inc. as lead sponsor.

NCT NCT07872306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07872306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Followed by an Active Treatment Period to Evaluate the Safety, Tolerability, and Efficacy of SAT-3247 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
Lead sponsor
Satellos Bioscience, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 15, 2026
Completion date
June 30, 2029
Enrollment
51 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

facioscapulohumeral muscular dystrophy (fshd)